Trial · NCT04741880
Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial)
NCT04741880, Phase 2, Phase 3, Unknown, Instituto Nacional de Cancer, Brazil
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial). Trials, record NCT04741880. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04741880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial)
- NCT number
- NCT04741880
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Instituto Nacional de Cancer, Brazil
- Conditions
- Anesthesia, Cancer
- Interventions
- Lidocaine IV, Saline
- First posted
- 2021-02-05
- Last updated
- 2021-07-30
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to T12 regression of the sensory block | Period: Day 0 postoperative | Time between the injection of bupivacaine into the subarachnoid space and the regression of sensory block to T12 dermatome (in minutes) |
| Secondary | Time to motor block regression | Day 0 postoperative | Time between the injection of bupivacaine into the subarachnoid space and the regression of motor block to the modified Bromage scale 1 (in minutes) |
| Secondary | Most rostral dermatome achieved by the sensory block | Day 0 postoperative | Evaluated as ordinal variable (see statistical analysis) |
| Secondary | Time to two-segment regression of the sensory block | Day 0 postoperative | Time between the injection of bupivacaine into the subarachnoid space and the regression of 2 dermatomes sensory block level (in minutes) |
| Secondary | Propofol dose at the operating room | Intraoperative | In mg |
| Secondary | Time to the first opioid rescue | Intraoperative | In mg |
| Secondary | Postoperative pain score at rest | Admission to the PACU, 2 postoperative hours, 24 postoperative hours, and worse in the first 24 postoperative hours measurements | Verbal numerical scale between 0 and 10, being 0 = "no pain" and 10 = "worst pain imaginable" |
| Secondary | Pain score at movement | 24 postoperative hours | Verbal numerical scale between 0 and 10, being 0 = "no pain" and 10 = "worst pain imaginable" |
| Secondary | Quality of recovery in 24 hours | 24 postoperative hours | Quality of recovery measured by the "40-item quality-of-recovery questionnaire" (QoR-40) |
| Secondary | Need for opioid analgesics (binary) | Between 0 and 6 postoperative hours, between 6 and 24 postoperative hours, and between 0 and 24 postoperative hours | YES/NO |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers21
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04741880
GET https://conductscience.org/api/trials/v1/NCT04741880/papers?page=2